News Formal

Regeneron Pharma’s adjusted earnings beat estimates

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 16 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 97%

United States News News

United States United States Latest News,United States United States Headlines

Steve Gelsi covers banking and cannabis as a Senior Reporter for MarketWatch.

Regeneron Pharmaceuticals Inc.’s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regeneron said its third-quarter net income fell 23% to $1 billion, or $8.89 a share, from $1.

32 billion, or $11.66 a share, in the year-ago quarter. Third-quarter adjusted profit rose to $11.59 a share from $11.14 a share in the year-ago period and beat the FactSet consensus estimate of $10.68 a share. Revenue climbed 15% to $3.36 billion, ahead of the Wall Street analyst expectation of $3.23 billion.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Ares Acquisition Corp., X-energy scrap $1.8B merger due to ‘persistently volatile public markets’Steve Gelsi covers banking and cannabis as a Senior Reporter for MarketWatch.
Source: MarketWatch - 🏆 3. / 97 Read more »